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Introduction: By providing timely care at all steps along the
continuum of lung cancer care, providers may be able to limit
disease progression before treatment and possibly improve clinical
outcomes. This study examines the timeliness of key events in the
process of care between initial radiograph and first treatment.
Methods: Dates of key events were extracted from the medical
records of 2463 veterans receiving lung cancer care at 133 Depart-
ment of Veterans Affairs (VA) facilities. After reviewing their site’s
abstraction results, facility leaders completed a survey on their
perceptions of their local processes of lung cancer care.
Results: Median time from first radiography to first treatment was
71 days. The longest intermediate time interval examined was
between first treatment referral and first treatment (median  12
days). Time from first to last diagnostic test was most variable
(interquartile range  0–27 days). We found a significant trend
indicating that the time interval from first radiograph to treatment
was shorter for patients with more advanced disease. This effect was
also significant within six of the seven intermediate time intervals
we examined. Survey responses indicated that the chart review
process stimulated improvement activity.
Conclusions: Although patients with earlier stage disease benefit more
from treatment, they do not proceed as quickly through the continuum
of care as patients with more advanced disease. By measuring variabil-
ity in timeliness of care at multiple steps in the lung cancer care process,
facilities may identify opportunities for improvement.
Key Words: Quality of care, Lung cancer, access, Timeliness,
Veterans.
(J Thorac Oncol. 2008;3: 951–957)
Lung cancer is the most common cause of cancer mortalityworldwide.1 Overall, the 5-year lung cancer survival rate
is only 16%.2 However, this rate varies considerably by stage.
Nearly half (49%) of patients with localized cancer survive
five or more years from diagnosis, compared with only 3% of
patients with distant metastasis.2 By providing timely care at
all steps along the continuum of lung cancer care, providers
may be able to limit disease progression before treatment,3
increase patient satisfaction,4–6 and possibly improve clinical
outcomes.
Previous research on lung cancer care processes indi-
cates that a high degree of variability exists in the timeliness
of lung cancer care.7–9 Identifying causes of this variation is
an essential component in quality management. One potential
source of systematic variation is disease stage. Some evi-
dence suggests that patients with more advanced disease
receive care more quickly than patients with earlier stage
disease,10,11 although this was not found to be the case in all
studies.12–14 If patients with more advanced disease do in fact
receive care more quickly, it would be beneficial to identify
where along the continuum of care this variation occurs. By
identifying the source, one can better determine whether this
variation represents suboptimal care and, if necessary, iden-
tify improvement strategies.
The purpose of this article is to examine time intervals
between steps along the continuum of lung cancer care for
patients at VA hospitals and to test the hypothesis that
patients with more advanced disease experience shorter time
intervals between steps as they progress through this contin-
uum of care. To better understand how the examination of lag
times across the continuum of lung cancer care may facilitate
local process improvement, we also summarize the concerns
and barriers to improvement identified by facility leaders as a
result of their site’s participation in this study and the im-




In February and March of 2006, the VA administered a
retrospective chart review survey to assess timeliness of lung
cancer care. Surveys were distributed through email to per-
sonnel at each of the VA’s 139 medical centers who were
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familiar with their facility’s electronic medical record system
and processes of lung cancer diagnosis and care. Facilities
were asked to review the electronic medical records of 20
consecutive patients who received a pathologic diagnosis of
lung cancer before September 1, 2005. This data was origi-
nally collected as part of a VA lung cancer quality improve-
ment project. A request to analyze this data for research
purposes was approved by the Institutional Review Board of
the Minneapolis VA Medical Center.
In total, 133 VA facilities (95%) completed the survey.
Facilities extracted data on 2492 patients. We excluded 13
patients because no information was provided on their date of
diagnosis or any events before diagnosis. An additional 16
patients with an initial abnormal radiography date before
2002 were excluded because their experiences may not reflect
current lung cancer care practices. The remaining 2463 pa-
tients were included in our analyses.
Data Collection
For each patient, chart abstractors at the facility used a
standardized chart review form to record dates of key events
along the continuum of lung cancer care and cancer stage at
time of diagnosis. After the chart review had been completed,
each facility’s chief of staff and quality officer were asked to
review a summary of their medical center’s chart review data
and participate in a brief facility leadership survey. All 133
participating facilities completed this leadership survey. The
following questions were included in this survey: (1) Have
any concerns/issues regarding your facility’s practices arisen
as a result of the information discovered during the chart
reviews? (2) Please describe any changes/strategies you are
considering to address these issues; (3) What are your facil-
ity’s greatest barriers to rapid early diagnosis of lung cancer
and appropriate care? Following each of these questions was
a text box in which respondents could type in responses.
Time Interval Measures
Dates were collected for each of the following events:
(1) first radiograph with a lung abnormality (defined as the
first date reported by chart abstractors of a suspicious nodule
or mass on an x-ray, computed tomography (CT), or magnetic
resonance imaging image—if abstractors indicated that the
patient had repeated scans, the date of the first scan was
used); (2) patient informed of radiography results; (3) first
diagnostic test (diagnostic test defined as any lung cancer
related evaluative procedure occurring after the first radio-
graph and before diagnosis including any imaging tests fol-
lowing the initial radiograph); (4) last diagnostic test; (5)
diagnosis (defined as the date a positive pathology report
confirming lung cancer was signed—if the diagnosis date was
after the treatment date, the diagnosis date was left blank and
these patients were excluded from analyses of all time inter-
vals that begin or end with the date of diagnosis); (6) patient
informed of diagnosis; (7) first referral for treatment (defined
as the earliest date following initial radiography on which the
patient was referred for radiation therapy, chemotherapy, or a
surgical treatment procedure); and (8) first treatment (defined
as the earliest date following diagnosis on which the patient
received radiation therapy, chemotherapy, or a surgical treat-
ment). We calculated the time intervals between each sequen-
tial step in the continuum of lung cancer care, as well as the
overall time interval between first radiograph and first treat-
ment. Additionally, we calculated time intervals between first
radiography and first treatment for three different forms of
first treatment: radiation therapy, chemotherapy, and surgery.
Analyses
We present the median, interquartile range, and mean
for seven key time intervals on the continuum of lung cancer
care. All comparative and inferential analyses are conducted
on medians because all time interval distributions were pos-
itively skewed. Patients on the high end of these distributions
have dramatic effect on means but have no more effect on
medians than any other patient in the sample.
For each time interval analysis we excluded cases with
either a missing start or end date. Medians for each interval
are also reported by disease stage. To test the hypothesis that
patients with more advanced disease receive expedited care
we conducted Jonckheere-Terpstra trend tests15 on each time
interval. For each trend test, we excluded cases with missing
stage data as well as cases with missing start or end points.
We also report the distribution of responses to three questions
from the facility leadership survey. Two-sided p-values less
than 0.05 were considered to be significant. All analyses were
performed using SPSS (version 15.0.0, Chicago, IL).
RESULTS
Timeliness of Steps in Along the Continuum of
Lung Cancer Care
Figure 1 displays the median and interquartile ranges
for time intervals between first radiography of a lesion and
first treatment. The longest median time interval was between
first treatment referral and first treatment (12 days). The
largest interquartile range among the intermediate steps was
between first and last diagnostic test (27 days). Compared
with other steps in the process, communicating results to
patients occurred relatively quickly. The median time to inform
patients of their radiography result was 1 day and the median
delay in informing patients of their diagnosis was 2 days.
Timeliness and Disease Severity
At the time of diagnosis, 418 patients (17%) had stage
I disease, 260 (11%) stage II disease, 633 (26%) stage III
disease, and 841 (34%) stage IV disease. Stage was not
identified by abstractors in 311 patients (13%). Overall,
median time from first radiography to first treatment was 71
days; however this varied considerably by stage (Table 1).
We found a highly significant trend indicating that the time to
treatment was shorter among patients with more advanced
disease. This trend was significant regardless of whether the first
treatment was radiation therapy, chemotherapy, or surgery.
Figure 2 illustrates the relationship between disease
severity and timeliness for each of seven intermediate steps
between first radiography and first treatment. With the ex-
ception of the time interval between the last diagnostic test
and diagnosis, all trend tests were significant, indicating that
patients with more advanced disease progress through the
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continuum of care more quickly than patients with more
limited disease.
Facility Leadership Survey
Ninety-one facilities (68%) expressed one or more
concerns that arose as a result of reviewing their lung cancer
chart abstraction data. Among those stating concerns, the
most common category of concern mentioned was delay at
one or more step in process (45%). Coordination of care
(29%) and documentation issues (15%) were also commonly
mentioned. Eighty facilities (60%) indicated that one or more
changes or improvement activities were being considered as
a result of the study. Of these facilities, the most commonly
mentioned actions were educating providers regarding survey
results (29%); conducting a more comprehensive lung cancer
patient chart review (24%); and hiring additional personnel or
obtaining additional capital resources (18%).
One or more perceived barriers to timely lung cancer
care were listed by 114 participating facilities (86%). Table 2
lists commonly mentioned barriers. The most frequently
mentioned general category of barriers was lack of resources.
Process inefficiencies and patient barriers were each men-
tioned by over one third of facilities. A subgroup analysis
revealed that compared with sites mentioning resource or
patient barriers but not mentioning process inefficiencies,
facilities mentioning process inefficiencies were significantly
more likely to indicate that they were considering one or
FIGURE 1. Median, interquartile range, and mean days associated with intermediate steps in lung cancer care continuum of
care.




1st Radiography to Treatment by Form of Treatment
Radiation Therapy* Chemotherapy* Surgery
Median 71 67 64 87
Interquartile range 39–121 35–118 36–117 59–136
N 1377 501 636 331
Time to treatment by stage
Stage I median 95 96 110 91
N 227 51 50 130
Stage II median 98 105 100 91
N 181 43 58 87
Stage III median 69 72 68 82
N 439 200 238 62
Stage IV median 48 39 49 59
N 426 169 241 29
Jonckheere-Terpstra Statistic 12.31 7.96 7.06 3.28
p 0.001 0.001 0.001 0.001
*91 patients received chemoradiation as their first form of treatment. These patients are included in both the radiation therapy and
chemotherapy columns of this table.
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more changes or improvement activities (49 versus 75%,
Chi-Square  7.01, p value  0.008).
DISCUSSION
In this article, we examine the timeliness of care re-
ceived by VA lung cancer patients for seven intermediate
steps between the initial radiographic image of a lesion and
first treatment. Facilities wishing to improve upon their pro-
cesses of lung cancer care may benefit by conducting more
detailed chart reviews focusing on the time intervals that are
the longest and have the greatest variability. In our research,
the longest time lag occurred between first treatment referral
and first treatment (median  12 days). Multiple factors may
contribute to this time lag including limited availability of
treatment resources, the need for pretreatment evaluative
procedures, and patient preferences. The greatest variability
occurred between first and last diagnostic test (interquartile
range  0–27 days). This finding may reflect the complex
nature of diagnosing lung cancer. The types and number of
diagnostic tests performed depends on tumor size and loca-
TABLE 2. Perceived Barriers to Rapid Early Diagnosis of
Lung Cancer and Appropriate Care, as Reported by Facility
Leaders
Barrier* Number Mentioning %
Lack of resources 54 40.6
No/insufficient access to MRI/PET/CT 20 15.0
Lack of specialty services 18 13.5
Inadequate staffing 12 9.0
Process inefficiencies/inadequacies 46 34.6
Problems in coordination of care 13 9.8
Lack of follow-up communication with
patient
9 6.8
Delay in diagnostic radiology testing 7 5.3
Delay in referral to specialty clinics 7 5.3
Problems obtaining info from referral 7 5.3
Patient barriers 44 33.1
Patient noncompliance 23 17.3
Patient delays in reporting symptoms 17 12.8
Distance of patients from site 14 10.5
*Barrier categories receiving less than seven mentions are not reported.
FIGURE 2. Median days and interquartile range associated with intermediate steps in lung cancer care continuum of care by
stage.
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tion, patient characteristics and preferences, physician orien-
tation and resource availability, among other factors.
The median time across all steps in this process—from
initial radiograph to first treatment—was 71 days. This time
interval was somewhat shorter for patients who received radia-
tion therapy and/or chemotherapy as their first treatment (me-
dians  67 and 64 days, respectively) and was longer among
patients who underwent surgery as their first treatment (me-
dian  87 days). These intervals are similar to those from
other research. For example, in two single-site studies of VA
lung cancer patients the median times from symptom presen-
tation to treatment were 827 and 84 days16; in a British
sample, the median time from first radiograph to surgery was
80 days17; and in a Japanese sample the median time from
presentation to radiation therapy was 66 days.9
The longer times to treatment experienced by surgery
patients in our research may be justified considering that,
compared with patients receiving radiation therapy or che-
motherapy as their first form of treatment, surgical patients
often require more preliminary testing to assess resectability
and to determine if the patient will be able to tolerate the
procedure. However, it should also be noted that surgical resec-
tion is the most potentially curative option, thus the benefits of
reduced time lags may be greater for these patients.
We found a highly significant trend indicating that for
patients with more advanced disease the time interval from
first radiograph to treatment was shorter than for patients with
more limited disease. This effect was also significant within
six of the seven intermediate time intervals we examined. The
one step where this relationship was not found was between
the last diagnostic test and diagnosis. This is perhaps to be
expected, given the fact that this time interval is controlled
primarily by laboratory personnel who have no direct contact
with the patient.
Our findings regarding the relationship between time-
liness and disease stage are consistent with a Finnish study
reporting that patients with later stage lung cancer experi-
enced shorter intervals between first specialist appointment
and diagnosis11 and with a Swedish study indicating that
symptom-to-treatment delay was shorter among patients with
Stage IV disease than among other lung cancer patients.10
Although we found three other studies that failed to demon-
strate a significant relationship between disease stage and
timeliness of lung cancer care, the reported results of two of
these studies indicate a nonsignificant trend in a direction that
is consistent with our findings.12,13 The third did not provide
enough detail to determine if there was a nonsignificant
directional trend.14
The consistency in our data of the relationship between
disease stage and timeliness of care across all but one step
along the continuum of care suggests that this phenomenon is
unlikely to be attributable to any single causal variable. This
effect is, for example, not simply a function of patients with
more advanced cancer requiring fewer diagnostic tests. If that
were the case, we would have only found a relationship
between stage and timeliness in the interval between first and
last diagnostic test (Figure 2) and not between other steps in
the care process. Nor does this phenomenon appear to be
solely due to patient behaviors or preferences. Although
patients may be able to influence some of the reported time
intervals, it seems unlikely that they would have much con-
trol over when they are informed of their initial radiograph
result or of their diagnosis. Another potential explanation for
the effect is that patients with more limited disease are better
candidates for surgery and therefore more likely to be sub-
jected to time-consuming preoperative testing. However, the
fact that the relationship between stage and time to treatment
was highly significant even when radiation therapy, chemo-
therapy, and surgery patients were each examined separately
indicates that the phenomenon can not be explained by
differences in the distribution of treatment type by stage.
The discovery of early stage tumors is often the result
of an incidental finding of a chest radiograph. It is possible
that, in the absence of symptoms, patients feel less urgency to
receive treatment. These asymptomatic patients are also more
likely to proceed through the diagnosis and staging process
on an outpatient basis, thus the coordination of patient visits
may create additional delays. We did not have the necessary
data available to assess the relationship between presence of
symptoms and time to treatment; however an earlier single-
facility study of British patients admitted for lung tumor
resection found that time to surgery was significantly shorter
among patients diagnosed incidentally than for those present-
ing with symptoms (means  71 and 119 days respectively).13
Additional research is needed to determine if the presentation
of symptoms is related to timeliness of treatment among other
populations.
We are unable to ascertain from our results the degree
to which the relatively longer time intervals experienced by
earlier stage patients represents an opportunity for improve-
ment. This finding may reflect appropriate prioritization of
care if patients with the more acute symptoms, more con-
cerning radiographic findings, or diagnosed as having the
most advanced disease warrant expedited diagnosis and treat-
ment. It may also reflect appropriate care in cases where a
decision is made to manage patients with a solitary pulmo-
nary nodule through a strategy of “watchful waiting” or when
additional testing is required to diagnose and determine
appropriate treatment of patients in earlier stages. If however,
the relatively longer time lags experienced by early stage
patients are not an intentional part of the of the disease
management plan, then the fast-tracking of patients with
advanced disease may inappropriately shift resources away
from the patients who are most likely to benefit from treat-
ment. If this is the case, facilities may be able to improve their
lung cancer care processes by developing a more formal
prioritization system that weighs both case urgency and the
prognosis associated with treatment.
Our results also suggest that the nature of the relation-
ship between disease stage and timeliness of care may make
it difficult to determine how timeliness affects survival. This
may help to explain why some studies have found shorter
times to treatment to be associated with longer survival 18–20
others have found no association 7,21,22 and still others report
an inverse relationship.10,23,24 If, as our results suggest, pa-
tients with more advanced disease (and therefore less favor-
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able prognoses) receive treatment more quickly, the true
relationship between time to treatment and survival is likely
to be confounded by disease stage. Indeed, Neal and col-
leagues found that compared with standard referrals, urgent
referrals through a two-week diagnostic fast track system had
more advanced disease and poorer survival.25 Future research
should control for disease stage when examining the effect of
time to treatment on survival and other outcomes. Addition-
ally stage should be established as early as possible in this
research (eg, clinical stage based on CT scan findings),
because patients with the longest times to diagnosis and
treatment may progress to a more advanced stage during the
evaluation period.
Without more detailed information on each case, it is
difficult to determine whether the time lags between steps in
the continuum of care that we report are excessive. However,
responses from the facility leadership survey that was in-
cluded in this project suggest that there is room for improve-
ment. Over two-thirds of participating facilities expressed
one or more concerns that arose as a result of their chart
reviews and nearly as many indicated that they were consid-
ering specific changes or improvement activities. Most of the
barriers to improvement listed by facility leaders fell into one
of three groups: resource constraints (eg, limited access to
diagnostic equipment), patient issues (eg, noncompliance)
and process inefficiencies (eg, inadequate coordination of
care). This third category may be most directly amenable
through the application of quality improvement strategies.
Indeed compared with facilities listing patient or resource
barriers but not process inefficiencies, sites that mentioned
process inefficiencies as a barrier were more likely to indicate
that one or more improvement activities were being consid-
ered. It is possible however, that the underlying cause of
many resource and patient barriers are also process ineffi-
ciencies. Within the VA we have seen facilities use quality
improvement strategies to identify more efficient ways to use
resources and to improve patient cancellation and no-show
rates. Although resource limitations and patient variables
may set an upper bound on the quality of care that can be
provided when all process inefficiencies have been elimi-
nated, we believe that the identification of these barriers
should be followed up with more in-depth analyses of the
factors that affect resource utilization and patient behavior.
This study has several limitations. First, dates associ-
ated with each step in the process were not available for all
participants, and therefore sample sizes for each analysis
varied based on data availability. If there were nonrandom
differences in cases with missing dates, our estimates of delay
may be affected. Second, our retrospective chart reviews
were conducted by local staff at participating VA facilities
and we were unable to conduct reliability analyses across
abstractors. To keep the chart abstraction manageable we
were unable to capture all of the data that could potentially be
relevant to timeliness of care. Because of these data collec-
tion limitations, we were for example unable to identify Stage
1a versus Stage 1b tumors, to determine if the initial radio-
graph was x-ray, CT or magnetic resonance imaging on all
patients, or to assess whether procedures were conducted on
an inpatient or outpatient basis. Each of these variables may
have affected time treatment. Third, 5% of VA medical
centers did not submit data, and it is possible that lung cancer
care practices from these sites differ from those of partici-
pating facilities. However, the fact that we obtained data from
95% of VA medical centers suggests that nonresponse bias
was unlikely to have dramatically influenced our results.
Fourth, we did not control for facility level variables that may
have confounded our results. For example if the stage distri-
bution of patients varies across facilities nonrandomly by
variables such as academic affiliation or diagnostic practices,
then the association between stage and timeliness that we
found may actually be due to these facility level factors.
Finally, our sample consisted exclusively of veterans receiv-
ing care through the VA Healthcare System. Our results may
not be generalizable to other populations or settings. How-
ever, times to treatment in our research were similar to those
found in non-VA studies.9,17,26
Even with these limitations, this study makes a unique
and important contribution to our understanding of lung
cancer care practices. This work provides guidance for qual-
ity improvement efforts by identify the longest and most
variable time intervals along the continuum of lung cancer
care. Additionally, it is, to our knowledge, the first study to
report the relationship between timeliness of care and lung
cancer disease stage in a multisite sample or to examine this
relationship at multiple time intervals. Future research should
seek to identify the specific causes of variability at the most
time-consuming steps in the care process and to ascertain
whether it is appropriate for patients with later stage disease
to receive quicker care at each step. Improvement work
should not focus exclusively on minimizing time to treat-
ment, since much of this time may be necessary, but should
instead attempt to identify and eliminate unintended or un-
necessary delays.
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